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In the past fifteen years, far reaching advances have been achieved in the
field of chemotherapy. Many of the bacterial and rickettsial diseases today re-
spond to one or more of the newer chemotherapeutic agents or antibiotics. On
the other hand, the clinical course of most of the systemic fungous diseases is
not altered by the present antibiotics. Although the antibiotics have not been
shown to have a potentiating effect upon fungous diseases, the common com-
plication of moniliasis following antibiotic therapy has been observed by a num-
ber of investigators (2—4). Hammer, et al. (1) compared the in vitro activity of a
number of the antibiotics and potassium iodide against a large group of fungi.
The authors concluded that potassium iodide had no marked effect on fungous
growth in vitro even in concentrations higher than could be achieved in blood
levels. Of the antibiotics tested in vitro, chioromycetin, neomycin, and terramy-
cm showed greater activity than aureomycin, bacitracin, fumagillin, penicillin,
or streptomycin.
In this laboratory it has been demonstrated (5) that Di-Paralene is effective
in vitro against many of the fungi causing systemic mycosis. In view of these
observations and the low toxicity of the drug (6) studies on its in vitro effective-
ness against Candida albicans and Cryptococcus neoformans infections were in-
stituted.
MATERIALS AND METHODS
Twenty-one day-old male white mice were used throughout these experiments. The
mice were inoculated by the intraperitoneal route, and cultures of the lungs, spleen, liver,
and kidneys were made from the animals that died spontaneously on or before the 45th day
after inoculation. The cultures were made on Sabouraud's glucose agar containing 30 units
of penicillin and 30 units of streptomycin per milliliter. The cultures were incubated at 37°C.
The role of gastric mucin in lowering host resistance to fungous infections has been
clearly shown by a number of investigators (7—9). The five per cent gastric mucin was pre-
pared as follows: Granular mucin (Type 1701—W, Wilson Laboratories) was suspended in a
Waring blendor to a concentration of 5% in distilled water. After standing for 24 hours, the
pH was adjusted to 7.2 with one normal sodium hydroxide and the suspension filtered
through cheesecloth. The mucin suspension was intermittently sterilized, 15 minutes at 10
pounds pressure, on three successive days. The five per cent mucin was mixed with an equal
amount of fungous cells suspended in sterile saline prior to animal inoculation.
The strain of Candida albicans used was isolated from a case of generalized cutaneous
moniliasis, and the strain of Cryptococcus neoformans was isolated from a fatal case of torula
meningitis. Both cultures were maintained in the laboratory on Sabouraud's dextrose agar
slants.
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The cells utilized for inoculation were grown in flasks of Sabouraud's maltose broth
for 48 hours at 37°C. Following this period of incubation the cells were washed three times
in sterile saline and finally resuspended in a sufficient volume of mucin solution to give
the desired number of cells per milliliter. The number of cells was determined by means of
a Spencer hemacytometer. Plate counts were not made because the cells tend to form
groups making such counts inaccurate.
Varying concentrations of Di-Paralene were prepared in distilled water and the resulting
solution autoclaved for 20 minutes at 15 pounds. Experimental mice receiving the drug
or control mice receiving sterile saline solution, were injected with 0.1 ml. daily for 45 days
by the subcutaneous route in the groin region. Mice were held 15 days beyond the termina-
tion of the experiment to observe any deaths which might occur following the cessation of
drug therapy.
Mice that died within 48 hours after infection were not included in the data. Such deaths
were assumed to be due to trauma or other causes rather than the effects of the specific
infection.
RESULTS
For experiments I and II, C. neoformans was employed as the test Organism.
The mice were infected with approximately 1 X 106 cells suspended in a gastric
mucin. Group A mice received 0.25 mg. of Di-Paralene (10 mg./kg.) daily.
Group B received 0.375 mg. (15 mg./kg.); Group C, 0.5 mg. (20 mg./kg.); and
Group D, 0.675 mg. (25 mg./kg.). There were two control groups; one non-in-
fected which received a single injection of gastric mucin solution followed by
daily injections of 0.675 mg. of Di-Paralene, the other infected which received
0.1 ml. of sterile saline daily. The data from experiments I and II is incorporated
into Table I as the two experiments were comparable, differing only in the time
of the drug being instituted.
Only 30 per cent of the control group died, thus giving doubtful significance
to the findings with the test group. The results must be considered inconclusive,
although there was some evidence to indicate that there was a greater mortality
rate in the groups of mice receiving Di-Paralene.
In a second series of experiments C. albicans was employed as the infecting
organism. Twenty-one day-old white mice were inoculated intraperitoneally
with 8 X 106 cells suspended in mucin. Two levels of Di-Paralene were used;
0.625 mg./mouse (25 mg./kg.) and 0.25 mg./mouse (10 mg./kg.).
Table II represents a composite of four experiments using C. albicans as the
infectious agent. The mortality in the control group of 54.5 per cent indicated
that the strain of C. albicans employed was of lower pathogenicity than the
isolate 3148 employed by Salvin, et at. (9). The Candida strain used by us pro-
duced fewer toxic deaths within the first week of infection than that used by
Salvin, et at. The number of deaths occurring among our experimental mice
during the first seven days of infection never exceeded five per cent as opposed
to the 20 per cent reported by other authors (9).
There appeared to be a lowered mortality rate in the mice which received the
drug one and two days prior to infection, but due to the small numbers of mice
employed, the figures do not have statistical significance. Mice receiving the
drug one and two days post infection showed a marked increase in mortality in
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TABLE I
Effect of Di-Paralene on C. neoformans infections in mice
GROUP NUMBER MG DRUG/DAY DATE DRUG STARTED MORTALITY* % MORTALITY
Group A-i
Group A-2
Group A-3
Group A-4
Group B-i
Group B-2
Group B-3
Group B-4
Group C-i
Group C-2
Group C-3
Group C-4
Group D-1
Group D-2
Group D-3
Group D-4
Non-infected
controls E
Infected con-
trols F
0.25
0.25
0.25
0.25
0.375
0.375
0.375
0.375
0.5
0.5
0.5
0.5
0.625
0.625
0.625
0.625
0.625
0.1 ml. sterile
saline daily
2 days pre-infection
day of infection
1 day post-infection
2 days post-infection
2 days pre-infection
day of infection
1 day post-infection
2 days post-infection
2 days pre-infection
day of infection
1 day post-infection
2 days post-infection
2 days pre-infection
day of infection
1 day post-infection
2 days post-infection
Started same time as Group
A-i, B-i, C-i, and D-1
Started same time as Group
A-i, B-i, C-i, and D-i
6/10
3/10
4/10
4/10
4/10
2/10
7/10
4/10
3/10
5/10
5/10
2/10
6/10
5/10
4/10
6/10
10/20
6/20
60
30
40
40
40
20
70
40
30
50
50
20
60
50
40
60
0.0
30
Total no. of mice 200
* The numerator indicates the mortality and the denominator the total number of mice
on experiment.
TABLE II
-_______________
Effect of Di-Paralene on C. albicans infections in mice
GROUP NUMBER
—
MG. DRUG/DAY DATE DRUG STARTED MORTALITY*
— ____________
Group A-i 0.25 2 days pre-infection 2/10 20
Group A-2 0.25 day of infection 3/10 30
Group A-3 0.25 1 day post-infection 41/50 81.8
Group A-4 0.25 2 days post-infection 29/48 60.5
Group B-i 0.625 2 days pre-infection 2/10 20
Group B-2 0.625 day of infection 3/10 30
Group B-3 0.625 1 day post-infection 28/50 56.2
Group B-4 0.625 2 days post-infection 31/50 62
Non-infected 0.625 Started same time as Group 0/29 0.0
Controls C A-i and B-i
Infected Con- 0.1 ml. sterile Started same time as Group 24/44 54.5
trols D saline daily A-i and B-i
Total no. of mice 211
* Numerator indicates the mortality and the denominator the total number of mice
on experiment.
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three out of four of the groups. Mice receiving the lower level of the drug one
day post-infection showed the highest mortality (81.8 per cent). The other three
groups similarily treated after the infecting dose, showed increases in mortality
ranging from two to eight per cent over the control group. No deaths were ob-
served in the non-infected mice receiving drug alone.
DISCUSSION
Although there was some indication that mice receiving the drug prior to in-
fection were in some degree protected as indicated by a lower mortality rate,
the difference between these and the control group was not of statistical signifi-
cance. Further, these experiments were conducted in an effort to evaluate the
efficacy of Di-Paralene as an antifungal agent against established fungous in-
fections. The results indicate that groups of mice receiving the drug following
infection had a higher mortality rate than the control mice. Thus there appears
to be some evidence that the drug had a potentiating effect upon these infec-
tions.
Roth, et al. (6) have established the acute toxicity levels of Di-Paralene by a
number of routes and have evidence of the chronic toxic level when administered
orally. We have, during the course of these experiments, established the fact that
dosages of 10 mg./kg. to 25 mg./kg. when given daily to mice by the subcutane-
ous route provoke no abnormal responses or findings. Histologic sections on
control mice receiving 25 mg/kg. daily for 45 days showed no significant ab-
normalities.
Cultures on two out of five mice which developed encephalitis during the
course of the experiments showed the presence of C. albicans in the brain. Cul-
tures were negative on the other three mice. As there was no correlation between
the total dosage, and the development of encephalitis, it was felt that the drug
was not incriminated. These five mice represent slightly less than one per cent of
the total number of mice on experiment.
CONCLUSIONS
1. Di-Paralene at the dosage employed did not demonstrate therapeutic
value, but on the contrary appears to have a potentiating effect upon systemic
infections in mice with C. albicans and C. neoformans.
2. Mice are able to tolerate dosages up to 25 mg./kg. of Di-Paralene daily for
45 days without any evidence of acute or cumulative toxicity.
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